Comparative study of ASCA (Anti–Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease

Vermeire, Séverine; Joossens, Sofie; Peeters, Marc; Monsuur, Fred; Mariën, Godelieve; Bossuyt, Xavier; Groenen, Peter M.A.; Vlietinck, Robert; Rutgeerts, Paul

doi:10.1053/gast.2001.22546

Cited by 130 publications

(97 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Prometheus ASCA IgG assay, however, detected only 14 of the 32 positives (43.8%) detected by ARUP (Table 2). These findings are in agreement with a study from Belgium by Vermeire et al (41), which showed the INOVA ASCA IgG assay to be 23% more sensitive than the ASCA IgG assay performed at Prometheus. Discord between these ASCA EIAs is most likely due to differences in their cutoff values, as was demonstrated in the study by Vermeire et al using clinically defined sera (41).…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Analysis of Serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease

Jaskowski

Litwin

Hill

2006

Clin Vaccine Immunol

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is the general term used for a heterogeneous group of intestinal disorders, including Crohn's disease (CD) and ulcerative colitis (UC). Serological markers such as anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophilic cytoplasmic antibody (atypical pANCA) have proven useful in the diagnosis and differentiation of CD and UC. Immunoglobulin A (IgA) antibody directed against the outer membrane protein C (OmpC) of Escherichia coli is said by one group to have clinical utility in diagnosing IBD, specifically in ASCA-negative CD patients. Our objective in this study was to compare the results obtained from two separate laboratories offering similar IBD tests using sera from suspected IBD patients. One hundred ninety-seven sera received for IBD testing were included in the study. The agreement between the two laboratories was 93.4% for ASCA IgA, 90.9% for ASCA IgG, and 87.8% for atypical pANCA IgG. There were 25 sera with ASCA-negative/OmpC-positive results reported by one laboratory. Thirteen of these 25 (52.0%) ASCA-negative/OmpC-positive sera were also atypical pANCA positive (9 as determined by both laboratories, 3 by one, and 1 by the other). Atypical pANCA antibody is found primarily in IBD patients with UC and colon-limited CD (Crohn's colitis). We conclude that the ASCA and atypical pANCA assays showed good agreement between the two laboratories, but the data for ASCA-negative/OmpCpositive sera suggest that many (52.0%) of these patients were more likely to have had UC or Crohn's colitis based on the presence of an atypical pANCA.Crohn's disease (CD) and ulcerative colitis (UC) are the two major forms of inflammatory bowel disease (IBD). Both CD and UC are chronic, affecting children and adults (men and women almost equally), and are most common in northern Europe and North America. The onset of CD and UC is usually between the ages of 15 and 30, with a second, smaller peak of incidence between the ages of 50 and 70 (4, 23). Approximately 20% of individuals with CD have a biological relative with some form of IBD, and several reports have noted an increase in the prevalence of CD and UC in various geographic regions (2,17,24,36).Although there are many theories about the etiology of CD and UC, none have been proven. Many of the symptoms of CD and UC are similar, and diagnosis is often difficult, time-consuming, and invasive. Since CD and UC are treated differently, correct diagnosis and differentiation are medically important.Two serological markers have been found to have clinical utility in diagnosing IBD and aiding in the differentiation of CD from UC: anti-Saccharomyces cerevisiae antibody (ASCA) (immunoglobulin A [IgA] and/or IgG), using enzyme immunoassay (EIA) techniques, and antineutrophil cytoplasmic antibody (ANCA) (IgG) that demonstrates atypical perinuclear staining (pANCA), using indirect fluorescent-antibody assay (IFA) techniques. ASCA is directed against mannose sequences in the cell wall of Saccharomyces cerevisiae (26,35) and...

show abstract

Section: Discussionsupporting

confidence: 93%

“…ASCA antibodies are currently identified using commercial or in-house-developed EIAs. Independent studies have shown differences in sensitivity and specificity between some of the ASCA EIAs that are currently available (13,16,20,41).The atypical pANCA (ethanol-positive/formalin-negative) …”

mentioning

confidence: 99%

Analysis of Serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease

Jaskowski

Litwin

Hill

2006

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…A comparative study revealed a wide range in sensitivities and specificities among 4 assays (3 commercially available assays and the assay developed in Lille, Centre Hospitalier Réegional Universitaire, France), mainly as a consequence of the cutoff values chosen (39 ). The agreement among the assays was good (39 ).…”

Section: Anti-saccharomyces Cerevisiae Antibodiesmentioning

confidence: 99%

Serologic Markers in Inflammatory Bowel Disease

Bossuyt¹

2006

Clinical Chemistry

Self Cite

184

136

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is an enduring disease involving mostly young people, with symptoms of bloody diarrhea and abdominal cramps. Several antibodies have been associated with IBD, the 2 most comprehensively studied being autoantibodies to neutrophils (atypical perinuclear anti-neutrophil cytoplasmic antibodies) and anti-Saccharomyces cerevisiae antibodies. This review focuses on the value of these antibodies for diagnosing IBD, differentiating Crohn disease from ulcerative colitis, indeterminate colitis, monitoring disease, defining clinical phenotypes, predicting response to therapy, and as subclinical markers. Pancreatic antibodies and newly identified anti-microbial antibodies (anti-outer membrane porin C, anti-I2, and anti-flagellin) are also reviewed.

show abstract

“…Apart from ethnic differences, this might at least in part be explained by methodical reasons. In the study by Vermeire et al [25], four different ASCA ELISA tests were compared. The range in sensitivity was 41–76% and the specificity ranged between 88.5 and 97.5%.…”

Section: Discussionmentioning

confidence: 99%

Anti-<i>Saccharomyces cerevisiae</i> Antibodies in Patients with Inflammatory Bowel Disease and Their First-Degree Relatives: Potential Clinical Value

Glas¹,

Török²,

Vilsmaier³

et al. 2002

Digestion

View full text Add to dashboard Cite

Anti-Saccharomyces cerevisiae antibodies (ASCA) have been described as specific markers in Crohn’s disease and their healthy first-degree relatives. 171 patients with Crohn’s disease, their 105 first-degree relatives, 145 patients with ulcerative colitis and 101 first-degree relatives of patients with ulcerative colitis, 50 patients with infectious enterocolitis and 100 healthy controls were tested for ASCA employing the ELISA technique. When compared with the healthy controls (p < 0.0001) and patients with infectious enterocolitis (p < 0.0001) the prevalence of ASCA was significantly increased in patients with Crohn’s disease and their first-degree relatives (p < 0.01). Further significant differences concerning the frequency of ASCA within the different groups of our study population were not observed. In particular, ASCA were not found in increased prevalence in infectious enterocolitis. These observations are compatible with a role of ASCA as a marker of genetic predisposition to Crohn’s disease.

show abstract

Comparative study of ASCA (Anti–Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease

Cited by 130 publications

References 13 publications

Analysis of Serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease

Analysis of Serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease

Serologic Markers in Inflammatory Bowel Disease

Anti-<i>Saccharomyces cerevisiae</i> Antibodies in Patients with Inflammatory Bowel Disease and Their First-Degree Relatives: Potential Clinical Value

Contact Info

Product

Resources

About